High-dose vitamin D and fall risk is worth revisiting for a reason beyond vitamin D itself. It’s one of the clearest available examples of a pattern that keeps catching people out — including researchers who designed the trials.
Most of us carry two assumptions about dose. First, more of a good thing produces more effect. Second, if there’s a limit, the worst case is that extra does nothing.
Both assumptions have failed, repeatedly, in supplement trials.
Case one: vitamin D and falls
The short version, since we covered the detail in the previous post.
A single annual dose of 500,000 IU given to 2,256 women aged 70 and over raised falls by 15% and fractures by 26% compared with placebo[4]. The excess clustered in the three months after each dose.
A separate trial comparing monthly regimens found significantly more fallers on 60,000 IU than on 24,000 IU[5]. Injurious falls ran two to two-and-a-half times higher on the larger dose[5].
Meanwhile trials using 700–800 IU daily reported reductions in falls[5].
Same nutrient. Opposite direction, depending on amount and schedule.
Case two: beta-carotene
This one is older and, if anything, starker.
Observational research had consistently linked diets rich in beta-carotene to lower lung cancer risk[2]. That’s a reasonable basis for a trial, and two large ones were built on it.
ATBC enrolled 29,133 male smokers in Finland and gave 20 mg of beta-carotene daily for five to eight years. The result was an 18% excess in cumulative lung cancer incidence and an 8% excess in overall mortality[2].
CARET tested 30 mg of beta-carotene plus 25,000 IU of vitamin A in 18,314 people at high risk of lung cancer. It was stopped 21 months early[1]. There were 28% more lung cancers and 17% more deaths in the intervention group, with a relative risk of 1.36 for lung cancer incidence[1].
Two details are worth holding onto.
The trials didn’t merely fail to help. They caused harm in the group they were meant to protect. And in CARET follow-up, elevated lung cancer risk persisted for years after participants stopped taking the supplements[1].
The shared pattern
Line the two cases up and the same sequence appears.
| Vitamin D and falls | Beta-carotene and lung cancer | |
| Starting evidence | Deficiency linked to falls | Diet rich in it linked to lower risk |
| Dose tested | Far above dietary intake | Far above dietary intake |
| Result | Falls and fractures increased | Cancer and mortality increased |
| Affected group | Older adults on bolus dosing | Smokers and asbestos-exposed |
| Trial outcome | Harm signal in several trials | Both trials stopped early |
[Table 1] Two cases of non-linear dose-response · Source: After each test[1][2][4][5]
Four features recur.
The starting evidence was observational. Something was associated with a good outcome, which is not the same as causing it.
The dose tested was pharmacologic, not dietary. Nobody eats 30 mg of beta-carotene from vegetables, and nobody gets 500,000 IU of vitamin D from sunlight in one afternoon.
The harm concentrated in a subgroup. Smokers in one case, older adults receiving bolus doses in the other.
The direction reversed. Not “no benefit” — the opposite of what was expected.
Why observational findings flip
The gap between the two kinds of study is the crux.
When people who eat more carrots get less lung cancer, the carrot is one candidate explanation among many. Those people may also smoke less, exercise more, or eat differently overall. The nutrient gets credit for a pattern it may only accompany.
Isolating that nutrient and giving it at ten or twenty times dietary levels is a different intervention entirely. It’s no longer “eating more vegetables.” It’s a concentrated compound at a dose the body has never encountered.
An analysis of β-carotene supplementation put the conclusion bluntly. The large trials make it highly unlikely that pharmacologic doses prevent most lung cancers, and provide strong evidence of adverse effects in smokers[3].
Reading a dose claim after this
A few habits that follow from these two cases.
Ask what kind of study produced the claim. “Associated with” and “reduced” are different verbs backed by different designs.
Compare the dose to dietary intake. If the amount tested is many multiples of what food provides, dietary evidence transfers poorly.
Look for who it worked in, and who it didn’t. Both these harms were subgroup effects. An overall average can hide them.
Treat “no upper limit needed” as a claim, not a default. The assumption that excess simply passes through has been wrong more than once.
Notice when trials stop early. It sometimes means overwhelming benefit. It also means what it meant in CARET.
A note for readers in Korea
Vitamin D is inexpensive and widely available here, including in monthly and injectable high-dose formats. Convenience is a real advantage for adherence — but the falls research found the harm signal specifically in bolus regimens, not in daily ones.
If a high-dose schedule has been suggested to you, that’s worth a conversation rather than an assumption. The question isn’t only how much, but how it’s spaced.
Closing
The useful takeaway isn’t about vitamin D or beta-carotene specifically. It’s that dose-response isn’t reliably a straight line, and the supplement conversation is largely built as though it were.
What struck me on reading these together was how reasonable each trial looked beforehand. Strong observational signal, plausible mechanism, a high-risk group who stood to gain most. The design errs toward a generous dose because that seems like the safest way to detect an effect.
That last instinct is the one the data keeps punishing.
At a Glance
- Vitamin D: 500,000 IU annually raised falls 15% and fractures 26%; 60,000 IU monthly produced more fallers than 24,000 IU; 700–800 IU daily reduced falls
- Beta-carotene: ATBC found 18% excess lung cancer and 8% excess mortality in smokers; CARET found 28% more cancers and 17% more deaths and stopped 21 months early
- Both started from observational evidence and tested pharmacologic doses
- Both produced harm, not merely absence of benefit
- Both concentrated harm in a subgroup that overall averages could obscure
- In CARET, elevated risk persisted years after supplementation stopped
- “Extra simply passes through” is an assumption, not an established default
※ This article is for general information and does not replace medical advice, diagnosis or treatment. It describes trial findings and is not guidance on any individual’s dosing. Do not start, stop or alter a supplement regimen on your own — particularly high-dose or bolus schedules — without discussing it with a clinician.
References
- Omenn GS et al., “Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial”, https://pubmed.ncbi.nlm.nih.gov/8901853/
- “β-Carotene supplementation and lung cancer incidence in the ATBC Study”, PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6636175
- “β-Carotene and lung cancer: a case study”, American Journal of Clinical Nutrition, https://ajcn.nutrition.org/article/S0002-9165(22)04459-8/fulltext
- Sanders KM et al., “Annual high-dose oral vitamin D and falls and fractures in older women”, JAMA 2010, https://pubmed.ncbi.nlm.nih.gov/20460620/
- “Impact of Vitamin D and Calcium on Falls and Fractures in Older Adults”, Endocrine Practice, https://www.endocrinepractice.org/article/S1530-891X(25)00965-6/fulltext